ALRN Aileron Therapeutics Inc.

-0.05  -3%
Previous Close 1.94
Open 1.94
Price To Book 1.07
Market Cap 27874618
Shares 14,748,475
Volume 35,185
Short Ratio
Av. Daily Volume 376,849

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Noted that development to be discontinued - no pivotal trial.
Peripheral T-cell lymphoma (PTCL)
Phase 1/1b interim data due 1H 2019 with final data 2H 2019.
ALRN-6924 and Cytarabine (Ara-C)
Acute myeloid leukemia (AML); Myelodysplastic syndrome (MDS)
Phase 2a commencement of enrolment in expansion cohort announced January 16, 2019 with preliminary data due 2H 2019.
ALRN-6924 and IBRANCE (palbociclib)
Solid tumors
Phase 1 trial to be initiated 1H 2019 with initial data due 2H 2019.
ALRN-6924 and Paclitaxel
Breast cancer